Viatris

Current directors and officers who also hold a role at another S&P 500 company.

• Frank A. DamelioHPE · DirectorHUM · DirectorZTS · Director
• Elisha W. FinneyMTD · Director
• Theodora MistrasEW · CFO

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

• Davis Selected AdvisersSched. 13G/A · as of Sep 30, 2026 · filing
  6.30%
  72,403,329 shares

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. May 4, 2026

   On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity. Ms. Mistras will cease to serve as Chief Financial Officer effective May 8, 2026 and will remain employed by the Company until May 22, 2026 for transition purposes. Ms. Mistras’ resignation was not related to any disagreement between Ms. Mistras and the Company on any matter relating to the Company’s accounting practices, financial statements, internal controls, or operations. On May 4, 2026, the Board of Directors of the Company (the “Board”) appointed Paul Campbell, Viatris’ current Chief Accounting Officer and Corporate Controller, to also serve as interim Chief Financial Officer of the Company, effective May 8, 2026, until a permanent Chief Financial Officer is appointed by the Board. Mr.

   Read the 8-K filing
2. Feb 3, 2026

   On February 3, 2026, Viatris Inc. (the “Company”) announced that Brian Roman, Chief Legal Officer of the Company, would transition from his role with the Company and cease to serve as Chief Legal Officer effective as of February 9, 2026. Mr. Roman will remain an employee of the Company until April 1, 2026 for transitional purposes. In connection with his departure from the Company, Mr. Roman will be eligible to receive separation payments equal to the sum of his base salary plus target bonus and a pro rata bonus for 2026, consistent with severance benefits paid to similarly situated executives. Mr. Roman would also execute a customary release of claims. On February 3, 2026, the Company also announced that Matthew Maletta will join the Company as Chief Legal Officer on February 9, 2026. Mr.

   Read the 8-K filing
3. Dec 5, 2025

   On August 4, 2025, Viatris Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) to report the appointment of David Simmons to the Board of Directors of the Company (the “Board”). At the time of the Initial 8-K, the Board had not determined the committee(s) to which Mr. Simmons would be named. This Amendment No. 1 to the Initial 8-K is being filed to report that on December 4, 2025, the Board appointed Mr. Simmons to serve on the Compensation Committee and the Science and Technology Committee, effective immediately after the 2025 annual meeting of shareholders.

   Read the 8-K filing
4. Aug 5, 2025

   Director Appointment On August 4, 2025, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 14 to 15 and appointed David Simmons as an independent (as defined in the applicable NASDAQ listing rules) member of the Board, effective immediately, with a term of office expiring at the Company’s 2025 annual meeting of shareholders (the “2025 Annual Meeting”). The Board anticipates naming Mr. Simmons to serve on one or more committees of the Board, but at the time of this Current Report on Form 8-K, has not determined the committee(s) to which Mr. Simmons will be named. The Company will file an amendment to this Current Report on Form 8-K naming those committees once they are determined. Mr.

   Read the 8-K filing
5. May 5, 2025

   Director Appointments On May 5, 2025, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 12 to 14 and appointed Frank D’Amelio and Michael Severino as independent (as defined in the applicable NASDAQ listing rules) members of the Board, effective immediately, with terms of office expiring at the Company’s 2025 annual meeting of shareholders (the “2025 Annual Meeting”). The Board appointed Mr. D’Amelio to the Finance Committee of the Board and Dr. Severino to the Science and Technology Committee of the Board, each appointment effective May 5, 2025. Mr. D’Amelio and Dr.

   Read the 8-K filing
6. Dec 6, 2024

   (e) Approval of an amendment to the Viatris Inc. 2020 Stock Incentive Plan. On December 6, 2024, Viatris Inc. (“Viatris” or the “Company”) held its 2024 annual meeting of shareholders (the “2024 Annual Meeting”). As further discussed below, at the 2024 Annual Meeting, shareholders of the Company approved an amendment to the Company’s 2020 Stock Incentive Plan (the “2020 Stock Incentive Plan Amendment”). For a description of the 2020 Stock Incentive Plan Amendment, see the Company’s Definitive Proxy Statement on Schedule 14A (File No. 001-39695), filed with the Securities and Exchange Commission on October 25, 2024 (the “Proxy Statement”). A copy of the 2020 Stock Incentive Plan Amendment is attached as Appendix C to such Proxy Statement.

   Read the 8-K filing
7. Jun 3, 2024

   Director Appointment On June 3, 2024, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 11 to 12 and appointed Rogério Vivaldi Coelho, M.D., M.B.A. as an independent (as defined in the applicable NASDAQ listing rules) member of the Board with a term of office expiring at the Company’s 2024 annual meeting of shareholders and appointed him to the recently reestablished Science and Technology Committee of the Board, each appointment effective June 3, 2024. Dr. Vivaldi will receive compensation for his role as an independent member of the Board consistent with the compensation of the Company’s other non-employee directors as disclosed in the Amendment to Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The Company has entered into an indemnification agreement with Dr.

   Read the 8-K filing
8. Dec 15, 2023

   On May 22, 2023, Viatris Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) to report the appointment of Leo Groothuis to the Board of Directors of the Company (the “Board”). At the time of the Initial 8-K, the Board had not determined the committee(s) to which Mr. Groothuis would be named. This Amendment No. 1 to the Initial 8-K is being filed to report that on December 14, 2023, the Board appointed Mr. Groothuis to serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee, effective immediately after the 2023 annual meeting of shareholders.

   Read the 8-K filing
9. Dec 15, 2023

   On December 14, 2023, Viatris Inc. (the “Company”) determined that Sanjeev Narula, Chief Financial Officer, would transition from his role with the Company and cease to serve as Chief Financial Officer effective as of March 1, 2024. Mr. Narula will be eligible to receive severance benefits equal to two times his base salary and target bonus, subject to a release of claims and other customary conditions. Mr. Narula will be eligible to receive a pro rata portion of his performance-based restricted stock units granted in 2022 and 2023 based on actual performance at the end of the applicable performance period. Other unvested equity awards that Mr. Narula holds as of his separation will be forfeited.

   Read the 8-K filing
10. Oct 20, 2023

    On October 20, 2023, Rajiv Malik, President, informed Viatris Inc. (the “Company”) of his intention to retire from his executive role with the Company effective as of April 1, 2024. To support the transition of Mr. Malik’s substantial operating responsibilities given his significant tenure with the Company and primary responsibility for operation of the Company’s complex manufacturing and commercial platform for over 15 years, and to assist and support the Company’s new Chief Executive Officer, the Company requested and Mr. Malik agreed to consult with the Company on all operational matters. Mr. Malik has also agreed to remain a member of the Board of Directors. Mr. Malik’s currently outstanding equity awards will continue vesting during his service (or earlier upon certain qualifying terminations of Board or consulting service). Mr.

    Read the 8-K filing
11. May 22, 2023

    Executive Chairman Transition On May 19, 2023, Robert J. Coury, the Executive Chairman of Viatris Inc. (the “Company” or “Viatris”), agreed with the independent members of the Board of Directors (the “Board”) to transition to a new role as Chairman Emeritus and Senior Strategic Advisor from the conclusion of the Company’s 2023 Annual Meeting of Shareholders (the “2023 Annual Meeting”) through the end of 2025 (the same period that Mr. Coury previously committed to the Company under his Executive Employment Agreement when Viatris was created). As a result of Mr. Coury’s agreement to serve in this advisory role, the independent members of the Board and Mr. Coury agreed that Mr. Coury will not stand for re-election at the 2023 Annual Meeting and will cease to be a director and to serve as an officer and employee of the Company effective as of the conclusion of the 2023 Annual Meeting.

    Read the 8-K filing
12. Feb 27, 2023

    On December 29, 2022, Viatris Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) to report the appointment of Elisha Finney and Scott Smith to the Board of Directors of the Company (the “Board”). At the time of the Initial 8-K, the Board had not determined the committee(s) to which Ms. Finney and Mr. Smith would be named. This Amendment No. 1 to the Initial 8-K is being filed to report that on February 24, 2023, the Board appointed Ms. Finney to serve on the Audit Committee and Finance Committee, effective immediately, and determined not to appoint Mr. Smith to serve on any committee of the Board.

    Read the 8-K filing
13. Feb 27, 2023

    On February 24, 2023, Viatris Inc. (the “Company”) appointed Scott A. Smith to serve as the Chief Executive Officer of the Company, effective as of April 1, 2023, and to hold such office until his successor is chosen and qualified in his stead or until his earlier death, resignation or removal. Mr. Smith, age 60, is currently on the Company’s Board of Directors (the “Board”) and most recently served as President of BioAtla, Inc. (“BioAtla”), a global biotechnology company focused on the development of Conditionally Active Biologics ™ antibody therapeutics, since 2018 and as a director of BioAtla since 2020. At BioAtla, Mr.

    Read the 8-K filing
14. Dec 29, 2022

    Director Retirements On December 28, 2022, Class I directors Neil Dimick and Ian Read each notified Viatris Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective immediately. Neither director’s retirement was the result of any disagreement between such director and the Company on any matter relating to the Company’s operations, policies, or practices. Director Appointments On December 29, 2022, the Board appointed Elisha Finney and Scott Smith to the Board, effective immediately. Ms. Finney and Mr. Smith are each Class I directors, with terms of office expiring at the Company’s 2023 annual meeting of shareholders. The Board anticipates naming Ms. Finney and Mr. Smith to serve on one or more committees of the Board, but at the time of this Current Report on Form 8-K, has not determined the committee(s) to which Ms. Finney and Mr.

    Read the 8-K filing
15. Nov 25, 2020

    On November 19, 2020 and November 20, 2020, the Compensation Committee of the Viatris Board of Directors (the “Compensation Committee”) and/or the independent members of the Viatris Board of Directors, as applicable, unanimously approved the following deal related and/or transitional compensation matters and general compensation framework for the Viatris executive officers. The Compensation Committee intends to establish the compensation plans and programs for Viatris on a going forward basis in the first quarter of 2021 along with corresponding incentive compensation metrics and targets for 2021 and beyond to align with Viatris’ strategic and financial goals.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.